< Back to latest news & events

Event

Microbiome Movement – Maternal & Infant Health Summit 2020

October 2020

Event date: 15th October 2020

HGF Partner Craig Thomson will be presenting at the Microbiome Movement – Maternal & Infant Health Summit 2020 on 15th October.

The 2nd Microbiome Movement – Maternal & Infant Health Summit returns as the only conference to unite large pharma, drug developers, academic KOL’s and paediatric clinicians to discuss the shared challenges of helping to configure the microbiome in the first 1000 days of life to reduce risk of chronic health conditions.

Join the conference to find out more about the latest data-driven research and hear discussions on how to shape future research to accelerate the field as we begin to unlock the secrets of the infant microbiome to proactively prevent disease.

HGF Partner Craig Thomson will be presenting on Thursday 15th October.

Build a Commercially Relevant Microbiome IP Portfolio: Maternal and Infant Health
  • Understand the multiple motivations for building an IP Portfolio: protect a monopoly of sales, attract investment, improve bargaining position with a collaborator/competitor
  • How to make a commercially relevant selection of what to protect and when
  • How to effectively fit IP strategy into the wider challenges of an innovative microbiome business.

Attendees

Latest updates

Event - 12th September 2025

Wolters Kluwer Breakfast Panel on AI & IP at AIPPI

Sofie McPherson, Patent Director at HGF, will be moderating a special breakfast panel session hosted by Wolters Kluwer at the AIPPI World Congress in Yokohama on 15 September 2025. Session …

Event details

T1465/23 – No Narrowing by Description—EPO Board Terminates Inventive Step Analysis for Arbitrary Modifications Citing G1/24 and G1/19

“The potential patentability of a specific narrow embodiment…cannot render a claim allowable which, due to its breadth, encompasses a multitude of other, non-inventive embodiments” – r. 3.5. Background EP3113515 was …

Read article

Wrestling with G1/24 – How should the claims be interpreted in view of the description?

In G1/24, the Enlarged Board of Appeal (EBA) codified how claims should be interpreted for assessing patentability: in consultation with the description. However, the decision was light on how, in …

Read article

Welcome to HGF Presents - New Video Series

Introducing HGF Presents a new video series delivering practical insights into European Patent Law and practice. Curated by our leading experts in chemistry, life sciences, technology & engineering, each concise …

Read article

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

Providing Enabling Disclosure for AI inventions at the EPO

  Video overview: The equivalent to the enablement requirement in the US at the EPO is Sufficiency. There is an increasing trend for the sufficiency of AI related patent applications …

Read article

Personalised Medicine Patenting of Known Drugs for Known Indications at the EPO

Video overview: The identification of specific sub-groups of patients to treat with a known drug, even if said patients may have been treated before with the drug, can yield patentable …

Read article